Search results
Results from the WOW.Com Content Network
Acute severe asthma, also known as status asthmaticus, is an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators (inhalers) and corticosteroids. [2] Asthma is caused by multiple genes , some having protective effect, with each gene having its own tendency to be influenced by the environment although a ...
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...
AERD affects an estimated 0.3–0.9% of the general population in the US, including around 7% of all asthmatics, about 14% of adults with severe asthma, and ~5-10% of patients with adult onset asthma. [2] [3] [8] AERD is uncommon among children, with around 6% of patients, predominantly female, reporting disease onset during childhood. [9]
Chemotherapy (often abbreviated chemo, sometimes CTX and CTx) is the type of cancer treatment that uses one or more anti-cancer drugs (chemotherapeutic agents or alkylating agents) in a standard regimen.
Acute severe asthma, previously known as status asthmaticus, is an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators and corticosteroids. [115] Half of cases are due to infections with others caused by allergen, air pollution, or insufficient or inappropriate medication use. [115]
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
Here’s how they affected whether or not patients would achieve 10% or greater weight loss: ... Semaglutide resulted in more than double the average weight loss of liraglutide (5.1% versus 2.2%). ...
Unwanted weight loss of more than 5% within 6 months. [2] [19] For people with a BMI of less than 20kg/m 2, weight loss of more than 2%. [2] [19] [27] For people with sarcopenia, weight loss of more than 2%. [2] [19] [27] New ways to score and stage cachexia are being explored, particularly in people with advanced cancer. [19]